Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 3,499 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Protein Control Clear all
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358
View directory record Official record
Conditions
Breast Neoplasms
Interventions
pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 29, 2026, 2:30 PM EDT
Recruiting Phase 1Phase 2 Interventional

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

NCT06904378
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
ONT01, Gemcitabine, Nab paclitaxel
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 29, 2026, 2:30 PM EDT
Terminated Phase 3 Interventional

Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma

NCT00198315
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Medpulser electroporation with Bleomycin, Tumor surgical excision
Combination Product · Procedure
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

NCT01777152
View directory record Official record
Conditions
Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma
Interventions
brentuximab vedotin, doxorubicin, prednisone, vincristine, cyclophosphamide
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
32
States / cities
Gilbert, Arizona • Duarte, California • Stanford, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 29, 2026, 2:30 PM EDT
Not yet recruiting Phase 3 Interventional

iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma

NCT07815574
View directory record Official record
Conditions
Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer
Interventions
iSCIB1+, Nivolumab & Ipilimumab, Placebo
Biological · Drug · Other
Lead sponsor
Scancell Ltd
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 1 Interventional

The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy

NCT01495962
View directory record Official record
Conditions
Wound; Abdomen, Abdominal Wall
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Rochester, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 29, 2026, 2:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects

NCT02372773
View directory record Official record
Conditions
Familial Frontotemporal Dementia
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
398 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
7
States / cities
San Francisco, California • Jacksonville, Florida • Charlestown, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)

NCT00891735
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
99
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 91 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 3 Interventional

Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer

NCT00046527
View directory record Official record
Conditions
Breast Neoplasms, Metastases, Neoplasm
Interventions
ABI-007
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
16 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2006 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 1 Interventional

Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers

NCT02506023
View directory record Official record
Conditions
Hemophilia A
Interventions
Desmopressin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

NCT02163759
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Adalimumab, Adalimumab Placebo, Etrolizumab, Etrolizumab Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
9
States / cities
Lakewood, Colorado • Maitland, Florida • Naples, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 29, 2026, 2:30 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180
View directory record Official record
Conditions
Cervical Cancer
Interventions
Sacituzumab Tirumotecan, Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
38
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy

NCT00468546
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
MabThera/Rituxan, Methotrexate, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
67
States / cities
Birmingham, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

NCT02876835
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat, Darbepoetin alfa, Placebo, Iron Therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
3,872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
161
States / cities
Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 128 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 29, 2026, 2:30 PM EDT
Not yet recruiting Phase 2 Interventional

Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients

NCT07390968
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
SARS-CoV-2 mRNA Vaccine ARCT-021, Tozinameran, Biospecimen Collection, Electronic Health Record Review, Survey Administration
Biological · Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose

NCT04977479
View directory record Official record
Conditions
Systemic Allergic Reaction
Interventions
Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Placebo, Pfizer-BioNTech COVID-19 Vaccine, Bivalent
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 69 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

NCT02285062
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
lenalidomide, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, prednisone, vincristine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 80 Years
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
22
States / cities
Fayetteville, Arkansas • Orange, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 4 Interventional Results available

N-of-1 Trials In Children With Hypertension

NCT03461003
View directory record Official record
Conditions
Pediatric Hypertension
Interventions
NICHE method, Usual care, Amlodipine, Lisinopril, Hydrochlorothiazide, Losartan
Other · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
10 Years to 22 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Graded Insulin Suppression Test P&F

NCT06592261
View directory record Official record
Conditions
Insulin Resistance, Hyperinsulinemia, Obesity, Healthy
Interventions
Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia), Octreotide Acetate, 6-45 ng/kg/min, Dextrose 20 % in Water, Glucagon, 0-0.5 ng/kg/min
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma

NCT00928018
View directory record Official record
Conditions
Non-hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
Sirolimus, Methotrexate, Tacrolimus, Cyclosporine, MMF
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 72 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

NCT01274182
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GP2013, MabThera, Rituxan
Biological
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
16
States / cities
Los Angeles, California • Lexington, Kentucky • Cumberland, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone

NCT00797823
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin, Asp(B28)-, Glucagon, Placebo
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 29, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)

NCT02227862
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Mylan's insulin glargine, Lantus®
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
72
States / cities
Bell Gardens, California • Fresno, California • Greenbrae, California + 64 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 29, 2026, 2:30 PM EDT
Withdrawn Phase 2 Interventional

Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia

NCT04956276
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia
Interventions
ALXN1830, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 29, 2026, 2:30 PM EDT